Insulin Infusion Pumps Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Pump Device, Infusion Set, and Reservoir), By Region and Competition 2020-2030F

Market Overview

The Global Insulin Infusion Pumps Market, valued at USD 1.55 Billion in 2024, is projected to experience a CAGR of 6.50% to reach USD 2.26 Billion by 2030. Insulin infusion pumps are medical devices providing continuous subcutaneous insulin delivery, offering an alternative to multiple daily injections for managing diabetes mellitus. The global market for these devices is primarily driven by the escalating prevalence of diabetes worldwide, coupled with the increasing demand for advanced and convenient glycemic management solutions that enhance patient outcomes. Furthermore, continuous technological advancements in pump design, integration with continuous glucose monitoring, and automated insulin delivery systems significantly bolster market expansion. According to the International Diabetes Federation, as of 2023, an estimated 540 million people worldwide were living with diabetes, underscoring the substantial patient base.

However, a significant impediment to market growth is the high cost associated with these devices and the varied, often limited, reimbursement policies across different regions. This financial barrier can restrict patient access, particularly in developing economies where healthcare infrastructure and affordability remain critical concerns.

Key Market Drivers

The global insulin infusion pumps market expansion is directly influenced by the persistent increase in worldwide diabetes diagnoses. This escalating patient demographic inherently broadens the addressable market for advanced glycemic management solutions. As more individuals are identified with diabetes, the demand for effective and less burdensome treatment modalities like insulin pumps intensifies, shifting away from conventional injection methods. According to the IDF Diabetes Atlas 2025, 589 million adults were living with diabetes worldwide in 2024, representing a substantial and growing patient base requiring ongoing insulin therapy. This expansive and continuously growing patient pool forms a fundamental driver, propelling the development and adoption of insulin pump technologies.

Complementing the rise in diabetes prevalence, significant technological advancements in insulin pump devices represent another critical driver for market growth. Innovations in automated insulin delivery systems, miniaturization, and seamless integration with continuous glucose monitors have transformed diabetes management. These advancements provide greater precision in insulin dosing and reduce the burden of frequent manual adjustments. According to Insulet's full year 2024 earnings report, the company achieved 500,000 estimated active global customers using Omnipod products, including 365,000 global customers using Omnipod 5, indicating significant adoption of advanced tubeless pump technology. Such progress improves patient adherence and satisfaction, fostering market penetration by offering increasingly convenient solutions. This innovation is vital considering the IDF Diabetes Atlas reported diabetes caused at least USD 1.015 trillion in global health expenditure in 2024.

Download Free Sample Report

Key Market Challenges

The significant cost associated with insulin infusion pumps, coupled with varied and often limited reimbursement policies across different regions, presents a substantial impediment to market expansion. The high upfront investment required for these advanced medical devices creates a considerable financial barrier for many patients, restricting their access to this beneficial diabetes management option. This issue is particularly pronounced in developing economies, where healthcare infrastructure is less robust and patient affordability is a critical concern, leading to reduced adoption rates despite the clear clinical advantages.

This financial burden directly affects the market's growth trajectory. For instance, according to the American Diabetes Association, prior to July 2023, the cost of insulin delivered via traditional pumps under Medicare Part B was not capped, indicating a higher financial outlay for patients before policy changes introduced a $35 monthly cap. Such elevated costs, even with some recent policy improvements in specific regions, continue to deter widespread patient uptake globally and limit market penetration, as a substantial portion of the patient base cannot afford these devices or their ongoing supplies.

Key Market Trends

The Global Insulin Infusion Pumps Market is undergoing significant evolution driven by targeted technological advancements and an expanding patient demographic.

The integration of Artificial Intelligence and Machine Learning for predictive dosing represents a pivotal trend, enhancing the precision and autonomy of insulin delivery systems. These intelligent algorithms analyze real-time glucose data, lifestyle factors, and historical patterns to forecast future glucose levels, proactively adjusting insulin delivery to prevent both hypoglycemic and hyperglycemic events. For instance, Tandem Diabetes Care's Control-IQ+ technology, cleared in May 2025, utilizes an advanced algorithm with an AutoBolus feature to predict glucose levels 30 minutes ahead and automatically adjust insulin every five minutes, thereby improving glucose control and simplifying diabetes management. This capability significantly reduces the cognitive burden on individuals managing diabetes, fostering greater adherence and improved therapeutic outcomes.

Another crucial trend is the increased adoption of insulin pumps for Type 2 Diabetes. Historically, insulin pumps were primarily associated with Type 1 diabetes, but advancements in pump technology and evolving clinical guidelines are broadening their application. Automated insulin delivery systems are demonstrating significant benefits in glycemic control for individuals with Type 2 diabetes, leading to a notable shift in treatment strategies. According to the American Diabetes Association's 2024 Standards of Care, continuous glucose monitoring, often integrated with pumps, is now considered to improve glycemic outcomes for older adults with Type 2 diabetes on insulin therapy. This expansion into a larger patient pool, combined with systems like the Omnipod 5 being evaluated in pivotal trials for Type 2 diabetes, indicates a substantial market growth opportunity.

Segmental Insights

The Pump Device segment is experiencing rapid growth in the Global Insulin Infusion Pumps Market, primarily driven by continuous technological advancements. These innovations include the development of smaller, more user-friendly designs and the crucial integration with continuous glucose monitoring (CGM) systems, leading to the emergence of automated insulin delivery (AID) or closed-loop systems. Such advanced pump devices offer superior glycemic control, reduce the burden of frequent manual adjustments, and enhance patient quality of life by automatically tuning insulin delivery based on real-time glucose levels. Furthermore, increasing regulatory approvals for these sophisticated devices, such as those from the U. S. Food and Drug Administration (FDA), bolster their market adoption and build healthcare professional confidence. This combination of innovation and regulatory support makes pump devices a preferred method for diabetes management.

Regional Insights

North America dominates the global insulin infusion pumps market due to a combination of distinct factors. The region exhibits a significant prevalence of diabetes, which drives substantial demand for advanced and efficient diabetes management solutions. This demand is effectively met by a well-established healthcare infrastructure and high patient awareness regarding innovative medical technologies. Furthermore, favorable reimbursement policies from institutions like Medicare, which cover insulin pumps, substantially improve patient access to these critical devices. The presence of major medical device companies and a supportive regulatory environment, exemplified by the Food and Drug Administration, also foster continuous product development and market growth.

Recent Developments

• In April 2025, Medtronic plc submitted 510(k) applications to the U.S. Food and Drug Administration for an interoperable insulin pump, specifically its MiniMed 780G system, intended for integration with a continuous glucose monitoring sensor developed by Abbott. This submission represented a crucial step in an ongoing global partnership between the two companies, aiming to provide expanded and flexible CGM options for users of Medtronic’s automated insulin delivery systems. The initiative underscored a commitment to offering greater choice and advanced solutions for diabetes management by combining leading insulin pump and CGM technologies.

• In June 2024, Insulet Corporation commenced the full commercial launch of its Omnipod 5 Automated Insulin Delivery System with Dexcom G7 sensor integration in the U.S. Concurrently, the company initiated a limited market release of its highly anticipated Omnipod 5 App for iPhone. These introductions enhanced the tubeless automated insulin delivery experience by offering compatibility with Dexcom’s latest generation CGM sensor and enabling full system control directly from a compatible iPhone. This dual launch provided individuals with type 1 diabetes more flexibility and choice in managing their condition through advanced connectivity and simplified mobile operation.

• In January 2024, Tandem Diabetes Care and Abbott announced a collaboration resulting in the integration of Tandem’s t:slim X2 insulin pump with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor. This marked the first automated insulin delivery system in the U.S. to offer compatibility with Abbott's FreeStyle Libre technology, providing users with a 15-day wear CGM option. The integration allowed the t:slim X2’s Control-IQ technology to automatically adjust insulin delivery based on minute-to-minute glucose readings from the Libre 2 Plus sensor, enhancing the therapeutic benefits of a hybrid closed-loop system for diabetes management.

• In 2024, Insulet Corporation expanded the indication for its Omnipod 5 Automated Insulin Delivery System to include adults with type 2 diabetes. This significant regulatory approval broadened the availability of tubeless automated insulin pump technology to a wider patient population. The system, previously approved for type 1 diabetes, offered an innovative approach to insulin management by providing continuous, rapid-acting insulin. This development addressed an unmet need for a simplified, wearable solution for individuals with type 2 diabetes who require insulin therapy, potentially reducing the burden associated with daily insulin injections and improving glycemic control.

Key Market Players

• Medtronic plc
• Insulet Corporation
• Ascensia Diabetes Care Holdings AG
• Tandem Diabetes Care, Inc.
• Ypsomed Holding AG

Report Scope:

In this report, the Global Insulin Infusion Pumps Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Insulin Infusion Pumps Market, By Component:

o   Pump Device

o   Infusion Set

o   Reservoir

• Insulin Infusion Pumps Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Insulin Infusion Pumps Market.

Available Customizations:

Global Insulin Infusion Pumps Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Insulin Infusion Pumps Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]